FDA Adverse Event Injury Summary report: N

ACRYSOF

MDR report key: 3181423 · Received June 14, 2013

Report

Report Number
1119421-2013-00662
Event Type
Injury
Date Received
June 14, 2013
Date of Event
January 1, 2013
Report Date
May 18, 2013
Manufacturer
ALCON RESEARCH, LTD. / HUNTINGTON
Product Code
HQL
PMA / PMN Number
P930014
Removal / Correction Number
NA
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
IN
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

THE PRODUCT HAS NOT BEEN RECEIVED FOR EVAL. PRODUCT HISTORY RECORDS COULD NOT BE REVIEWED BECAUSE THE REPORTER DID NOT PROVIDE A LENS SERIAL NUMBER, LOT NUMBER, OR ANY IDENTIFICATION TRACEABLE TO THE MFG DOCUMENTATION. ADD'L INFO HAS BEEN REQUESTED. (B)(4).

Description of Event or Problem · 1

A SURGEON NOTED THAT HE HAS ABOUT ONE IN TEN PTS THAT REPORTED EXPERIENCING NEGATIVE DYSPHOTOPSIA FOLLOWING INTRAOCULAR LENS (IOL) IMPLANT PROCEDURES. THESE PTS TYPICALLY REPORTED A SHADOW OBSTRUCTING THE TEMPORAL FIELD OF VISION. THE PT WOULD REPORT A FEELING AS IF HIS/HER EYE WAS CONSTRICTED FROM THE LATERAL SIDE. SOME PTS WOULD REPORT THIS AS A CONSTANT FLICKERING OF THE VISION TEMPORALLY. THE EVENT WOULD SUBSIDE FOLLOWING THE USE OF DILATOR EYE DROPS OF SUNGLASSES. THE SURGEON REPORTED THAT HE IS USING A DIFFERENT MODEL LENS NOW AND IS SEEING ONE IN FOUR PTS REPORTING DYSPHOTOPSIA. THE SURGEON DOES NOT FEEL THE PROBLEM IS RELATED TO THE SITE OF INCISION OR THE SIZE OF THE PUPIL, AS YOUNGER PTS WITH WIDER PUPILS ARE ALSO REPORTING NEGATIVE DYSPHOTOPSIA. THE SYMPTOMS ARE HIGHLY DISTURBING TO THE PT AND THEY INCREASE THE PTS DISSATISFACTION. THE SURGEON WONDERS IF THE SQUARE EDGE DESIGN OF THE LENSES CONTRIBUTES TO THESE EVENTS. THERE ARE TWO MEDICAL DEVICE REPORTS ASSOCIATED WITH THIS EVENT. THIS REPORT IS FOR THE FIRST LENS MODEL GROUP.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
272126 ACRYSOF INTRAOCULAR LEN HQL ALCON RESEARCH, LTD. / HUNTINGTON UNK UNK

Patients

Seq Age Sex Outcome Treatment
1 Required Intervention